Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

The effect of covalently bonded aryl layers on the band bending and electron density of SnO2 surfaces probed by synchrotron X-ray photoelectron spectroscopy.

Schuurman JC, McNeill AR, Martinez-Gazoni RF, Scott JI, Reeves RJ, Allen MW, Downard AJ.

Phys Chem Chem Phys. 2019 Aug 28;21(32):17913-17922. doi: 10.1039/c9cp03040a. Epub 2019 Aug 5.

PMID:
31380874
2.

Complement alone drives efficacy of a chimeric antigonococcal monoclonal antibody.

Gulati S, Beurskens FJ, de Kreuk BJ, Roza M, Zheng B, DeOliveira RB, Shaughnessy J, Nowak NA, Taylor RP, Botto M, He X, Ingalls RR, Woodruff TM, Song WC, Schuurman J, Rice PA, Ram S.

PLoS Biol. 2019 Jun 19;17(6):e3000323. doi: 10.1371/journal.pbio.3000323. eCollection 2019 Jun.

3.

Unraveling the Macromolecular Pathways of IgG Oligomerization and Complement Activation on Antigenic Surfaces.

Strasser J, de Jong RN, Beurskens FJ, Wang G, Heck AJR, Schuurman J, Parren PWHI, Hinterdorfer P, Preiner J.

Nano Lett. 2019 Jul 10;19(7):4787-4796. doi: 10.1021/acs.nanolett.9b02220. Epub 2019 Jun 11.

PMID:
31184907
4.

CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering.

Oostindie SC, van der Horst HJ, Lindorfer MA, Cook EM, Tupitza JC, Zent CS, Burack R, VanDerMeid KR, Strumane K, Chamuleau MED, Mutis T, de Jong RN, Schuurman J, Breij ECW, Beurskens FJ, Parren PWHI, Taylor RP.

Haematologica. 2019 Feb 21. pii: haematol.2018.207266. doi: 10.3324/haematol.2018.207266. [Epub ahead of print]

5.

Illness perceptions of stroke survivors: Predictors and changes over time - A 1 year follow-up study.

Groeneveld IF, van der Pas SL, Meesters JJL, Schuurman JM, van Meijeren-Pont W, Jagersma E, Goossens PH, Kaptein AA, Vliet Vlieland TPM; SCORE-study group.

J Psychosom Res. 2019 Jan;116:54-61. doi: 10.1016/j.jpsychores.2018.10.019. Epub 2018 Nov 2.

PMID:
30654994
6.

CD3-Bispecific Antibody Therapy Turns Solid Tumors into Inflammatory Sites but Does Not Install Protective Memory.

Benonisson H, Altıntaş I, Sluijter M, Verploegen S, Labrijn AF, Schuurhuis DH, Houtkamp MA, Verbeek JS, Schuurman J, van Hall T.

Mol Cancer Ther. 2019 Feb;18(2):312-322. doi: 10.1158/1535-7163.MCT-18-0679. Epub 2018 Oct 31.

PMID:
30381448
7.

Development and Testing of a Magnetic Resonance (MR) Conditional Afterloader for Source Tracking in Magnetic Resonance Imaging-Guided High-Dose-Rate (HDR) Brachytherapy.

Beld E, Seevinck PR, Schuurman J, Viergever MA, Lagendijk JJW, Moerland MA.

Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):960-968. doi: 10.1016/j.ijrobp.2018.04.066. Epub 2018 May 4.

PMID:
29891205
8.

Response to Comment on "Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells".

Engelberts PJ, Breij ECW, Valerius T, Schuurman J, Parren PWHI, Beurskens FJ.

J Immunol. 2018 Apr 15;200(8):2517. doi: 10.4049/jimmunol.1800233. No abstract available.

9.

Structures of C1-IgG1 provide insights into how danger pattern recognition activates complement.

Ugurlar D, Howes SC, de Kreuk BJ, Koning RI, de Jong RN, Beurskens FJ, Schuurman J, Koster AJ, Sharp TH, Parren PWHI, Gros P.

Science. 2018 Feb 16;359(6377):794-797. doi: 10.1126/science.aao4988.

PMID:
29449492
10.

Cysteine-SILAC Mass Spectrometry Enabling the Identification and Quantitation of Scrambled Interchain Disulfide Bonds: Preservation of Native Heavy-Light Chain Pairing in Bispecific IgGs Generated by Controlled Fab-arm Exchange.

van den Bremer ETJ, Labrijn AF, van den Boogaard R, Priem P, Scheffler K, Melis JPM, Schuurman J, Parren PWHI, de Jong RN.

Anal Chem. 2017 Oct 17;89(20):10873-10882. doi: 10.1021/acs.analchem.7b02543. Epub 2017 Oct 2.

PMID:
28922593
11.

Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9.

Taylor RP, Lindorfer MA, Cook EM, Beurskens FJ, Schuurman J, Parren PWHI, Zent CS, VanDerMeid KR, Burack R, Mizuno M, Morgan BP.

Clin Immunol. 2017 Aug;181:24-28. doi: 10.1016/j.clim.2017.05.016. Epub 2017 May 31.

12.

Efficient Generation of Bispecific Murine Antibodies for Pre-Clinical Investigations in Syngeneic Rodent Models.

Labrijn AF, Meesters JI, Bunce M, Armstrong AA, Somani S, Nesspor TC, Chiu ML, Altintaş I, Verploegen S, Schuurman J, Parren PWHI.

Sci Rep. 2017 May 30;7(1):2476. doi: 10.1038/s41598-017-02823-9.

13.

Hinge-deleted IgG4 blocker therapy for acetylcholine receptor myasthenia gravis in rhesus monkeys.

Losen M, Labrijn AF, van Kranen-Mastenbroek VH, Janmaat ML, Haanstra KG, Beurskens FJ, Vink T, Jonker M, 't Hart BA, Mané-Damas M, Molenaar PC, Martinez-Martinez P, van der Esch E, Schuurman J, de Baets MH, Parren PWHI.

Sci Rep. 2017 Apr 20;7(1):992. doi: 10.1038/s41598-017-01019-5.

14.

Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells.

Tammen A, Derer S, Schwanbeck R, Rösner T, Kretschmer A, Beurskens FJ, Schuurman J, Parren PW, Valerius T.

J Immunol. 2017 Feb 15;198(4):1585-1594. doi: 10.4049/jimmunol.1601268. Epub 2017 Jan 6.

15.

Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells.

Engelberts PJ, Voorhorst M, Schuurman J, van Meerten T, Bakker JM, Vink T, Mackus WJ, Breij EC, Derer S, Valerius T, van de Winkel JG, Parren PW, Beurskens FJ.

J Immunol. 2016 Dec 15;197(12):4829-4837. Epub 2016 Nov 2.

16.

Antibody Engineering & Therapeutics 2016: The Antibody Society's annual meeting, December 11-15, 2016, San Diego, CA.

Larrick JW, Alfenito MR, Scott JK, Parren PW, Burton DR, Bradbury AR, Lemere CA, Messer A, Huston JS, Carter PJ, Veldman T, Chester KA, Schuurman J, Adams GP, Reichert JM.

MAbs. 2016 Nov/Dec;8(8):1425-1434. Epub 2016 Aug 24.

17.

Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.

Cook EM, Lindorfer MA, van der Horst H, Oostindie S, Beurskens FJ, Schuurman J, Zent CS, Burack R, Parren PW, Taylor RP.

J Immunol. 2016 Sep 1;197(5):1762-75. doi: 10.4049/jimmunol.1600648. Epub 2016 Jul 29.

18.

Molecular Basis of Assembly and Activation of Complement Component C1 in Complex with Immunoglobulin G1 and Antigen.

Wang G, de Jong RN, van den Bremer ET, Beurskens FJ, Labrijn AF, Ugurlar D, Gros P, Schuurman J, Parren PW, Heck AJ.

Mol Cell. 2016 Jul 7;63(1):135-45. doi: 10.1016/j.molcel.2016.05.016. Epub 2016 Jun 16.

19.

A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.

Moores SL, Chiu ML, Bushey BS, Chevalier K, Luistro L, Dorn K, Brezski RJ, Haytko P, Kelly T, Wu SJ, Martin PL, Neijssen J, Parren PW, Schuurman J, Attar RM, Laquerre S, Lorenzi MV, Anderson GM.

Cancer Res. 2016 Jul 1;76(13):3942-53. doi: 10.1158/0008-5472.CAN-15-2833. Epub 2016 May 23.

20.

Editorial overview: Special section: New concepts in antibody therapeutics: What's in store for antibody therapy?

Schuurman J, Parren PW.

Curr Opin Immunol. 2016 Jun;40:vii-xiii. doi: 10.1016/j.coi.2016.04.001. Epub 2016 Apr 12. Review. No abstract available.

PMID:
27083411
21.

Response to "Comment on 'Comparison and uncertainty evaluation of different calibration protocols and ionization chambers for low-energy surface brachytherapy dosimetry' " [Med. Phys. 42, 4954-4964 (2015)].

Candela-Juan C, Vijande J, García-Martínez T, Niatsetski Y, Nauta G, Schuurman J, Ouhib Z, Ballester F, Perez-Calatayud J.

Med Phys. 2016 Apr;43(4):2007. doi: 10.1118/1.4942807. No abstract available.

PMID:
27036596
22.

A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface.

de Jong RN, Beurskens FJ, Verploegen S, Strumane K, van Kampen MD, Voorhorst M, Horstman W, Engelberts PJ, Oostindie SC, Wang G, Heck AJ, Schuurman J, Parren PW.

PLoS Biol. 2016 Jan 6;14(1):e1002344. doi: 10.1371/journal.pbio.1002344. eCollection 2016 Jan.

23.

Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells.

Lindorfer MA, Cook EM, Tupitza JC, Zent CS, Burack R, de Jong RN, Beurskens FJ, Schuurman J, Parren PW, Taylor RP.

Mol Immunol. 2016 Feb;70:13-23. doi: 10.1016/j.molimm.2015.12.007. Epub 2015 Dec 12.

PMID:
26690706
24.

Comparison and uncertainty evaluation of different calibration protocols and ionization chambers for low-energy surface brachytherapy dosimetry.

Candela-Juan C, Vijande J, García-Martínez T, Niatsetski Y, Nauta G, Schuurman J, Ouhib Z, Ballester F, Perez-Calatayud J.

Med Phys. 2015 Aug;42(8):4954-64. doi: 10.1118/1.4927059.

PMID:
26233221
25.

Complement in therapy and disease: Regulating the complement system with antibody-based therapeutics.

Melis JP, Strumane K, Ruuls SR, Beurskens FJ, Schuurman J, Parren PW.

Mol Immunol. 2015 Oct;67(2 Pt A):117-30. doi: 10.1016/j.molimm.2015.01.028. Epub 2015 Feb 17. Review.

26.

Controlled Fab-arm exchange for the generation of stable bispecific IgG1.

Labrijn AF, Meesters JI, Priem P, de Jong RN, van den Bremer ET, van Kampen MD, Gerritsen AF, Schuurman J, Parren PW.

Nat Protoc. 2014 Oct;9(10):2450-63. doi: 10.1038/nprot.2014.169. Epub 2014 Sep 25.

PMID:
25255089
27.

Opening the door to innovation.

Schuurman J, Graus YF, Labrijn AF, Ruuls S, Parren PW.

MAbs. 2014 Jul-Aug;6(4):812-9. doi: 10.4161/mabs.29004. Epub 2014 Apr 24. Review.

28.

Complement is activated by IgG hexamers assembled at the cell surface.

Diebolder CA, Beurskens FJ, de Jong RN, Koning RI, Strumane K, Lindorfer MA, Voorhorst M, Ugurlar D, Rosati S, Heck AJ, van de Winkel JG, Wilson IA, Koster AJ, Taylor RP, Saphire EO, Burton DR, Schuurman J, Gros P, Parren PW.

Science. 2014 Mar 14;343(6176):1260-3. doi: 10.1126/science.1248943.

29.

Mind the gap.

Schuurman J, W H I Parren P.

Methods. 2014 Jan 1;65(1):1-4. doi: 10.1016/j.ymeth.2013.10.012. Epub 2013 Oct 30. No abstract available.

PMID:
24184353
30.

Production of stable bispecific IgG1 by controlled Fab-arm exchange: scalability from bench to large-scale manufacturing by application of standard approaches.

Gramer MJ, van den Bremer ET, van Kampen MD, Kundu A, Kopfmann P, Etter E, Stinehelfer D, Long J, Lannom T, Noordergraaf EH, Gerritsen J, Labrijn AF, Schuurman J, van Berkel PH, Parren PW.

MAbs. 2013 Nov-Dec;5(6):962-73. doi: 10.4161/mabs.26233. Epub 2013 Aug 22.

31.

In-depth qualitative and quantitative analysis of composite glycosylation profiles and other micro-heterogeneity on intact monoclonal antibodies by high-resolution native mass spectrometry using a modified Orbitrap.

Rosati S, van den Bremer ET, Schuurman J, Parren PW, Kamerling JP, Heck AJ.

MAbs. 2013 Nov-Dec;5(6):917-24. doi: 10.4161/mabs.26282. Epub 2013 Aug 28.

32.

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange.

Labrijn AF, Meesters JI, de Goeij BE, van den Bremer ET, Neijssen J, van Kampen MD, Strumane K, Verploegen S, Kundu A, Gramer MJ, van Berkel PH, van de Winkel JG, Schuurman J, Parren PW.

Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5145-50. doi: 10.1073/pnas.1220145110. Epub 2013 Mar 11.

33.

Mutation of Y407 in the CH3 domain dramatically alters glycosylation and structure of human IgG.

Rose RJ, van Berkel PH, van den Bremer ET, Labrijn AF, Vink T, Schuurman J, Heck AJ, Parren PW.

MAbs. 2013 Mar-Apr;5(2):219-28. doi: 10.4161/mabs.23532. Epub 2013 Feb 13.

34.

Fab-arm exchange: what's in a name?

Schuurman J, Labrijn AF, Parren PW.

MAbs. 2012 Nov-Dec;4(6):636. doi: 10.4161/mabs.22075. Epub 2012 Sep 6. No abstract available.

35.

Fc-Fc interactions of human IgG4 require dissociation of heavy chains and are formed predominantly by the intra-chain hinge isomer.

Rispens T, Meesters J, den Bleker TH, Ooijevaar-De Heer P, Schuurman J, Parren PW, Labrijn A, Aalberse RC.

Mol Immunol. 2013 Jan;53(1-2):35-42. doi: 10.1016/j.molimm.2012.06.012. Epub 2012 Jul 10.

PMID:
22784992
36.

Hemorrhoidal artery ligation procedure with or without Doppler transducer in grade II and III hemorrhoidal disease: a blinded randomized clinical trial.

Schuurman JP, Borel Rinkes IH, Go PM.

Ann Surg. 2012 May;255(5):840-5. doi: 10.1097/SLA.0b013e31824e2bb5.

PMID:
22504188
37.

[Internal and external haemorrhoids].

Schuurman JP, Go PM.

Ned Tijdschr Geneeskd. 2011;155(36):A3113. Dutch.

PMID:
21914230
38.

Quantitative analysis of the interaction strength and dynamics of human IgG4 half molecules by native mass spectrometry.

Rose RJ, Labrijn AF, van den Bremer ET, Loverix S, Lasters I, van Berkel PH, van de Winkel JG, Schuurman J, Parren PW, Heck AJ.

Structure. 2011 Sep 7;19(9):1274-82. doi: 10.1016/j.str.2011.06.016.

39.

Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3-CH3 interaction strength.

Labrijn AF, Rispens T, Meesters J, Rose RJ, den Bleker TH, Loverix S, van den Bremer ET, Neijssen J, Vink T, Lasters I, Aalberse RC, Heck AJ, van de Winkel JG, Schuurman J, Parren PW.

J Immunol. 2011 Sep 15;187(6):3238-46. doi: 10.4049/jimmunol.1003336. Epub 2011 Aug 12.

40.

Current perspectives on management of congenital jugular vein aneurysms.

Kloppenburg GT, de Vries JP, Schuurman JP, Koelemij R, Wille J.

Vasc Endovascular Surg. 2011 Apr;45(3):237-40. doi: 10.1177/1538574410395952. Epub 2011 Feb 2.

PMID:
21289129
41.

Economic evaluation of pressure ulcer care: a cost minimization analysis of preventive strategies.

Schuurman JP, Schoonhoven L, Defloor T, van Engelshoven I, van Ramshorst B, Buskens E.

Nurs Econ. 2009 Nov-Dec;27(6):390-400, 415.

PMID:
20050490
42.

Endovascular therapy for recurrent type III endoleak.

Schuurman JP, Fioole B, van den Heuvel DA, de Vries JP.

Vasc Endovascular Surg. 2010 Feb;44(2):123-5. doi: 10.1177/1538574409345025. Epub 2009 Nov 25.

PMID:
19942599
43.

Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo.

Labrijn AF, Buijsse AO, van den Bremer ET, Verwilligen AY, Bleeker WK, Thorpe SJ, Killestein J, Polman CH, Aalberse RC, Schuurman J, van de Winkel JG, Parren PW.

Nat Biotechnol. 2009 Aug;27(8):767-71. doi: 10.1038/nbt.1553. Epub 2009 Jul 20.

PMID:
19620983
44.

Urinary bladder metastasis from an esophageal adenocarcinoma: a case report.

Schuurman JP, de Vries Reilingh TS, Roothaan SM, Bijleveld RT, Wiezer MJ.

Am J Gastroenterol. 2009 Jun;104(6):1603-4. doi: 10.1038/ajg.2009.113. Epub 2009 Apr 21. No abstract available.

PMID:
19491880
45.

Human IgG4 binds to IgG4 and conformationally altered IgG1 via Fc-Fc interactions.

Rispens T, Ooievaar-De Heer P, Vermeulen E, Schuurman J, van der Neut Kolfschoten M, Aalberse RC.

J Immunol. 2009 Apr 1;182(7):4275-81. doi: 10.4049/jimmunol.0804338.

46.

Immunoglobulin G4: an odd antibody.

Aalberse RC, Stapel SO, Schuurman J, Rispens T.

Clin Exp Allergy. 2009 Apr;39(4):469-77. doi: 10.1111/j.1365-2222.2009.03207.x. Epub 2009 Feb 13. Review.

PMID:
19222496
47.

Do pressure ulcers influence length of hospital stay in surgical cardiothoracic patients? A prospective evaluation.

Schuurman JP, Schoonhoven L, Keller BP, van Ramshorst B.

J Clin Nurs. 2009 Sep;18(17):2456-63. doi: 10.1111/j.1365-2702.2008.02711.x. Epub 2009 Feb 5.

PMID:
19220621
48.

Anatomical branches of the superior rectal artery in the distal rectum.

Schuurman JP, Go PM, Bleys RL.

Colorectal Dis. 2009 Nov;11(9):967-71. doi: 10.1111/j.1463-1318.2008.01729.x. Epub 2008 Oct 31.

PMID:
19175645
49.

Renal artery pseudoaneurysm caused by a complete stent fracture: a case report.

Schuurman JP, de Vries JP, Vos JA, Wille J.

J Vasc Surg. 2009 Jan;49(1):214-6. doi: 10.1016/j.jvs.2008.07.005.

50.

When binding is enough: nonactivating antibody formats.

Labrijn AF, Aalberse RC, Schuurman J.

Curr Opin Immunol. 2008 Aug;20(4):479-85. doi: 10.1016/j.coi.2008.05.010. Epub 2008 Jul 9. Review.

PMID:
18577454

Supplemental Content

Loading ...
Support Center